Company Overview of Rockefeller University
Rockefeller University is an educational institution, which focuses on medical research. It offers programs in fields such as biochemistry; structural biology and chemistry; medical sciences and human genetics; molecular, cell and developmental biology; immunology; virology and microbiology; neuroscience; physics; and mathematical biology. In addition the university offers Ph.D. degree in the Life Sciences. Rockefeller University was formerly known as Rockefeller Institute for Medical Research. It was established in 1901 and is based in New York City. The university has endowment assets worth $1372.2 million.
1230 York Ave
New York, NY 10021-6307
Founded in 1901
Key Executives for Rockefeller University
Trustee and Acting President
Compensation as of Fiscal Year 2015.
Rockefeller University Key Developments
Mabvax Therapeutics and The Rockefeller University Enter into a Collaborative Research Agreement
Aug 6 15
MabVax Therapeutics Holdings, Inc. The Rockefeller University's Laboratory of Molecular Genetics and Immunology have entered into a research collaboration agreement to explore the mechanism of action of constant region (Fc) variants of the HuMab 5B1 in the role of tumor clearance. The objective is to optimize Fc receptor
mediated antibody function. The work will be conducted in the Laboratory of Molecular Genetics and Immunology at The Rockefeller University. The Company recently announced that it will file investigational new drug (IND) applications with the U.S. Food and Drug Administration for a HuMab 5B1-based therapeutic product and a next generation PET imaging agent later this year. The Company anticipates initiating Phase I trials in the first quarter of 2016. Because the HuMab 5B1 antibody is fully human and recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, the Company believes that these antibodies reduce the likelihood of unwanted immunogenicity and cross reactivity. The results from preclinical studies continue to build the body of evidence that makes the HuMab 5B1 product a valuable asset. The Company believes that its unique dual-product development approach of having both a therapeutic and diagnostic application is applicable to other cancers utilizing the HuMab 5B1 antibody as well as with follow-on antibodies already under development in the preclinical pipeline.
Rockefeller University Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015
May 4 15
Rockefeller University Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015. Venue: Time Warner Center, New York, United States. Presentation Date & Speakers: May-05-2015, Kathleen Denis, Associate Vice President, Office of Technology Transfer, Kathleen A Denis, Associate Vice President, Office of Technology Transfer.
QR Pharma Begins Collaboration on Posiphen and Huntington’s Disease
Feb 4 15
QR Pharma, Inc. announced a new collaborative research agreement with The Rockefeller University aimed at developing a treatment for Huntington's disease (HD). The collaboration will focus on preclinical research involving QRâ s lead drug candidate, Posiphen Â®. Investigators at Rockefeller will conduct experiments in stem cell culture models of HD to determine, if Posiphen lowers the levels of the toxic huntingtin protein in these cells, if it promotes differentiation into neuronal cells and, if it prolongs the cell life of the HD cells. Results from the collaboration could lead to clinical studies in HD patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries